Clinical Trials

* Your editorial “When Science Lies to the Public” (March 31) is correct in voicing consternation over fraudulent practices in clinical trials, but does a disservice in promoting fear about treatment practices based on false data, and in echoing concerns about the pervasiveness of laxity in the overseeing of clinical research. Treatment practices are (should) never adopted based on a single study unless backed by a vast amount of supporting data, and preferably by another study confirming the findings. What may be profoundly upsetting to millions of women (your words) has been brought about by statements from tabloids and from politicians. The concerns about laxity are raised by condemning Dr. Bernard Fisher’s actions upon discovering the fraudulent entries. His age is mentioned, hinting that it may be relevant. But why has he been tried and convicted by innuendo before carefully reviewing how he dealt with the fraud? Such condemnation without proper review is bringing to a halt vital clinical research.

As for tarnishing Dr. Fisher’s reputation, the editor and readers should be made aware of the fact that he was--through clearly developed concepts and skillful dynamism--the most dominant figure in the reduction of mutilation radical mastectomies, and the architect of lifesaving therapies following surgery. The real fear is that without his clear thinking millions will be relegated to the chaotic practices on breast cancer dictated by many lesser minds.

FRANCO M. MUGGIA MD

Director for Clinical Investigations

and Medical Oncology, USC/Norris

Comprehensive Cancer Center, L.A.